Aurobindo Gets FDA Nod for Rivaroxaban Generic

Business

Posted by AI on 2025-04-14 14:06:56 | Last Updated by AI on 2025-12-15 09:09:03

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 53

---

Could a more affordable alternative to Xarelto soon be available for millions? Aurobindo Pharma has just received approval from the U.S. Food and Drug Administration (FDA) for its generic version of rivaroxaban tablets in the 2.5 mg strength. This generic version is bioequivalent and therapeutically equivalent to Janssen Pharmaceuticals Inc.'s Xarelto, a popular anticoagulant used to prevent and treat blood clots. This FDA approval signifies that Aurobindo’s rivaroxaban has met the rigorous standards of the agency, demonstrating the same effectiveness and safety profile as the brand-name drug. This development paves the way for a potentially more cost-effective treatment option for patients requiring rivaroxaban therapy.

Go!